Literature DB >> 21949126

Glycolytic and non-glycolytic functions of Mycobacterium tuberculosis fructose-1,6-bisphosphate aldolase, an essential enzyme produced by replicating and non-replicating bacilli.

Maria de la Paz Santangelo1, Petra M Gest, Marcelo E Guerin, Mathieu Coinçon, Ha Pham, Gavin Ryan, Susan E Puckett, John S Spencer, Mercedes Gonzalez-Juarrero, Racha Daher, Anne J Lenaerts, Dirk Schnappinger, Michel Therisod, Sabine Ehrt, Jurgen Sygusch, Mary Jackson.   

Abstract

The search for antituberculosis drugs active against persistent bacilli has led to our interest in metallodependent class II fructose-1,6-bisphosphate aldolase (FBA-tb), a key enzyme of gluconeogenesis absent from mammalian cells. Knock-out experiments at the fba-tb locus indicated that this gene is required for the growth of Mycobacterium tuberculosis on gluconeogenetic substrates and in glucose-containing medium. Surface labeling and enzymatic activity measurements revealed that this enzyme was exported to the cell surface of M. tuberculosis and produced under various axenic growth conditions including oxygen depletion and hence by non-replicating bacilli. Importantly, FBA-tb was also produced in vivo in the lungs of infected guinea pigs and mice. FBA-tb bound human plasmin(ogen) and protected FBA-tb-bound plasmin from regulation by α(2)-antiplasmin, suggestive of an involvement of this enzyme in host/pathogen interactions. The crystal structures of FBA-tb in the native form and in complex with a hydroxamate substrate analog were determined to 2.35- and 1.9-Å resolution, respectively. Whereas inhibitor attachment had no effect on the plasminogen binding activity of FBA-tb, it competed with the natural substrate of the enzyme, fructose 1,6-bisphosphate, and substantiated a previously unknown reaction mechanism associated with metallodependent aldolases involving recruitment of the catalytic zinc ion by the substrate upon active site binding. Altogether, our results highlight the potential of FBA-tb as a novel therapeutic target against both replicating and non-replicating bacilli.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21949126      PMCID: PMC3220552          DOI: 10.1074/jbc.M111.259440

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

2.  Carbon flux rerouting during Mycobacterium tuberculosis growth arrest.

Authors:  Lanbo Shi; Charles D Sohaskey; Carmen Pheiffer; Carmen Pfeiffer; Pratik Datta; Michael Parks; Johnjoe McFadden; Robert J North; Maria L Gennaro
Journal:  Mol Microbiol       Date:  2010-10-06       Impact factor: 3.501

3.  Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins.

Authors:  Jonathan D Crowe; Isla K Sievwright; Gillian C Auld; Norma R Moore; Neil A R Gow; Nuala A Booth
Journal:  Mol Microbiol       Date:  2003-03       Impact factor: 3.501

4.  The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.

Authors:  Simon S Gerber; Sofia Lejon; Michael Locher; Johann Schaller
Journal:  Cell Mol Life Sci       Date:  2010-01-29       Impact factor: 9.261

5.  Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection.

Authors:  Jennifer L Taylor; Jessica M Hattle; Steven A Dreitz; JoLynn M Troudt; Linda S Izzo; Randall J Basaraba; Ian M Orme; Lynn M Matrisian; Angelo A Izzo
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

6.  Kinetic properties of the glucose-6-phosphate and 6-phosphogluconate dehydrogenases from Corynebacterium glutamicum and their application for predicting pentose phosphate pathway flux in vivo.

Authors:  B Moritz; K Striegel; A A De Graaf; H Sahm
Journal:  Eur J Biochem       Date:  2000-06

7.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.

Authors:  J D McKinney; K Höner zu Bentrup; E J Muñoz-Elías; A Miczak; B Chen; W T Chan; D Swenson; J C Sacchettini; W R Jacobs; D G Russell
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins.

Authors:  Ida Rosenkrands; Richard A Slayden; Janne Crawford; Claus Aagaard; Clifton E Barry; Peter Andersen
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

9.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Molecular cloning, expression, purification, and characterization of fructose 1,6-bisphosphate aldolase from Mycobacterium tuberculosis--a novel Class II A tetramer.

Authors:  Peggy C Ramsaywak; Geneviève Labbé; Stefan Siemann; Gary I Dmitrienko; J Guy Guillemette
Journal:  Protein Expr Purif       Date:  2004-09       Impact factor: 1.650

View more
  31 in total

1.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

2.  Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from Mycobacterium tuberculosis.

Authors:  Scott D Pegan; Kamolchanok Rukseree; Glenn C Capodagli; Erica A Baker; Olga Krasnykh; Scott G Franzblau; Andrew D Mesecar
Journal:  Biochemistry       Date:  2013-01-18       Impact factor: 3.162

3.  ald of Mycobacterium tuberculosis encodes both the alanine dehydrogenase and the putative glycine dehydrogenase.

Authors:  Michelle M Giffin; Lucia Modesti; Ronald W Raab; Lawrence G Wayne; Charles D Sohaskey
Journal:  J Bacteriol       Date:  2011-12-30       Impact factor: 3.490

4.  The human milk protein-lipid complex HAMLET disrupts glycolysis and induces death in Streptococcus pneumoniae.

Authors:  Hazeline Roche-Hakansson; Goutham Vansarla; Laura R Marks; Anders P Hakansson
Journal:  J Biol Chem       Date:  2019-11-06       Impact factor: 5.157

5.  A noncompetitive inhibitor for Mycobacterium tuberculosis's class IIa fructose 1,6-bisphosphate aldolase.

Authors:  Glenn C Capodagli; Wafik G Sedhom; Mary Jackson; Kateri A Ahrendt; Scott D Pegan
Journal:  Biochemistry       Date:  2013-12-24       Impact factor: 3.162

6.  Regulated Expression Systems for Mycobacteria and Their Applications.

Authors:  Dirk Schnappinger; Sabine Ehrt
Journal:  Microbiol Spectr       Date:  2014

Review 7.  DHAP-dependent aldolases from (hyper)thermophiles: biochemistry and applications.

Authors:  Pierpaolo Falcicchio; Suzanne Wolterink-Van Loo; Maurice C R Franssen; John van der Oost
Journal:  Extremophiles       Date:  2013-10-29       Impact factor: 2.395

8.  Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.

Authors:  Anne Gründel; Melanie Pfeiffer; Enno Jacobs; Roger Dumke
Journal:  Infect Immun       Date:  2015-12-14       Impact factor: 3.441

9.  Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase.

Authors:  Andrei L Osterman; Irina Rodionova; Xiaoqing Li; Eduard Sergienko; Chen-Ting Ma; Antonino Catanzaro; Mark E Pettigrove; Robert W Reed; Rashmi Gupta; Kyle H Rohde; Konstantin V Korotkov; Leonardo Sorci
Journal:  ACS Chem Biol       Date:  2019-04-17       Impact factor: 5.100

10.  Surface-Shaving Proteomics of Mycobacterium marinum Identifies Biofilm Subtype-Specific Changes Affecting Virulence, Tolerance, and Persistence.

Authors:  Kirsi Savijoki; Henna Myllymäki; Hanna Luukinen; Lauri Paulamäki; Leena-Maija Vanha-Aho; Aleksandra Svorjova; Ilkka Miettinen; Adyary Fallarero; Teemu O Ihalainen; Jari Yli-Kauhaluoma; Tuula A Nyman; Mataleena Parikka
Journal:  mSystems       Date:  2021-06-22       Impact factor: 6.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.